News & Events

Cellular Dynamics International Appoints New Commercial, Operations and Financial Leadership

Download PDF

MADISON, Wis., December 16, 2008 – Cellular Dynamics International (CDI) announced today the appointment of three new executives to lead the company in its rapid growth and goal of industrializing stem cell technologies: Chris Kendrick-Parker, Chief Commercial Officer; Emile Nuwaysir, Chief Operating Officer; and David S. Snyder, Chief Financial Officer.

Kendrick-Parker brings more than 20 years of experience in the life science industry to CDI as chief commercial officer. Prior to CDI, he served as vice president of the global pharmaceutical business unit at Affymetrix, where he managed sales and marketing operations and aided in growing revenues to over $350 million per year within 8 years. Kendrick-Parker’s professional background also includes serving on the drug discovery services team at Amersham Pharmacia and over a decade of research in molecular and cellular biology in the Department of Human Oncology at the University of Wisconsin-Madison’s Comprehensive Cancer Center.

As chief operating officer, Nuwaysir is responsible for product development, manufacturing, and quality systems at CDI. Prior to joining the company, he served as senior vice president of program management and business development as well as chief technology officer at the Roche NimbleGen business unit within Roche Diagnostics. Prior to Roche NimbleGen, Nuwaysir held various scientific and managerial positions at NimbleGen Systems and was a postdoctoral researcher at the National Human Genome Research Institute and the National Institute of Environmental Health Sciences, where he helped establish what later became the National Center for Toxicogenomics.

Snyder has over 18 years of experience as a CFO in rapidly growing, entrepreneurial companies. Most recently, he served as site vice president and CFO of the Roche NimbleGen business unit within Roche Diagnostics. Snyder came to NimbleGen Systems to lead the company’s IPO, a process that eventually led to the sale of the company to Roche for $272.5 million. He brings extensive experience in the financing and general management of growth companies. Snyder has been the CFO of both private and public companies, and his experience not only includes start-ups but also one company that grew to nearly $2 billion in revenue and another that grew to nearly $3 billion in assets.

“We’re thrilled to have been able to recruit three of the top executives in the field,” said Robert Palay, Chairman and CEO of CDI. “With Chris, Emile and David on board, we have the best management team in the stem cell space and are now well positioned to be the leader in the pluripotent stem cell industry. Our goal is to be the low-cost, high-volume, high-quality leader in creating human iPS stem cell lines and in differentiating them into the high-quality tissue cells that our customers demand. We look forward to working closely with pharmaceutical customers, biotech companies and academia to provide them with the stem cell research tools they need.”

The company has gained momentum recently with the November announcement that it recently closed an $18 million financing round and merged with two other stem cell companies.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual’s stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI’s facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.